C
Collegium Pharmaceutical, Inc. (COLL)
NMS – Real Time Price. Currency in USD
35.69
-0.12 (-0.34%)
At close: May 12, 2026, 4:00 PM EDT
35.10
-0.59 (-1.65%)
After-hours: May 12, 2026, 4:37 PM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
35.69
-0.12 (-0.34%)
At close: May 12, 2026, 4:00 PM EDT
35.10
-0.59 (-1.65%)
After-hours: May 12, 2026, 4:37 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.71 | 2.52 | 8.0 | |
| Quick ratio | 1.62 | 1.78 | 8.0 | |
| Debt to Equity | 2.98 | -0.80 | 2.0 | |
| Debt to Assets | 0.56 | 0.73 | 4.0 | |
| Interest coverage | 2.02 | -13.90 | 6.0 | |
| Weighted average score | 5.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 464M | 567M | 631M | 781M | 796M |
| Gross Profit | 212M | 326M | 377M | 463M | 483M |
| Operating Income | 69M | 175M | 191M | 187M | 192M |
| Net Income | -25M | 48M | 69M | 63M | 75M |
| EBITDA | 204M | 325M | 360M | 413M | 418M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 4.8 | 0.94 | 3.0 |
| Next quarter | 0.64 | -10.65 | 1.5 |
| Current year | 4.88 | 0.81 | 3.0 |
| Next year | 4.13 | -4.93 | 2.5 |
| Weighted average score | 2.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -5.8 | -14.53 | -13.72 | -53.53 | 1.0 |
| Y/Y | 8.87 | 499.75 | 18.12 | 4.11 | 7.3 |
| 3y average | 19.07 | 109.05 | 23.7 | 52.99 | 9.8 |
| 5y average | 22.82 | 71.91 | 21.15 | 38.91 | 10 |
| Weighted average score | 7.0 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Total debt $929.7M significantly exceeds cash reserves ($288.5M), raising financial stability concerns
Total current assets $745.7M exceed Total current liabilities $435.0M, highlighting excellent liquidity
Debt-to-equity ratio (3.0) far exceeds the industry average, reflecting over-leverage
Interest coverage ratio (2x) is sufficient but not particularly strong
The company generates positive free cash flow $56.8M, supporting its financial health